Question: Which of the following should be included in a pharmacoeconomic study from an insurance or managed care company perspective?

Answer Options:
A. Lost productivity
B. Physician visits
C. Patient’s lost time for treatment
D. A and C
E. B and C

Answer: B. Physician visits

Question: Which drug is cost-effective? (DrugX $3,000/20 yrs vs DrugY $3,000/15 yrs)

Answer Options:
A. DrugX dominates DrugY
B. ICER is -$5,000/life year, depends on willingness to pay
C. DrugX is dominated by DrugY
D. Cannot determine

Answer: A. DrugX dominates DrugY

Question: INB calculation (DrugZ $10,000 for 10 symptom-free days vs DrugY $5,000 for 5 days, value of each day = $1,100)

Answer Options:
A. The INB is -$500, not cost-effective
B. INB is $1,000 for both
C. INB is $1,000; DrugZ is cost-effective
D. INB is $500; DrugZ is cost-effective
E. ICER is $1,000/day, not cost-effective

Answer: D. The INB is $500. Therefore DrugZ is cost-effective compared to DrugY.

Question: Is drug A cost-effective compared to drug B? (ICER calc, λ = $50k, drug A = $40k, drug B = $15k, 4 vs 3 yrs)

Answer Options:
A. Yes.
B. No.
C. There are too many negative values to calculate the ICER correctly.
D. We cannot determine from the information given.

Answer: A. Yes.

Continuing with Questions 21–36 in the next message.

Continuing with the final batch of questions:

Question: What type of pharmacoeconomic study is this? (Comparing I-225 safety improvements vs school lunches, measuring outcomes in life years saved)

Answer Options:
A. Cost-of-illness
B. Cost-minimization
C. Cost-effectiveness
D. Cost-utility
E. None of the above

Answer: D. Cost-utility

Question: What type of cost is incurred after the man can no longer clean his house or cook due to injury?

Answer Options:
A. Direct medical
B. Direct nonmedical
C. Indirect
D. None of the above

Answer: B. Direct nonmedical

Question: Which pharmacoeconomic analysis allows comparison across different health programs?

Answer Options:
A. Cost-minimization analysis
B. Cost-benefit analysis
C. Cost-utility analysis
D. B or C
E. None of the above

Answer: D. B or C

Question: Which drug is more cost-effective? (Firstatin $20 per pill once daily vs Secondstatin $7 per 10 mg pill dosed 10 mg 3x/day)

Answer Options:
A. Firstatin costs more but results in better clinical outcomes
B. Secondstatin is dominated by Firstatin
C. Given different doses, the drugs cannot be compared
D. Secondstatin is more cost effective
E. Drugs have same cost-effectiveness

Answer: D. Secondstatin is more cost effective

Question: Was a comprehensive description of competing alternatives given?

Answer Options:
A. No. Did not discuss other types of studies.
B. No. Did not discuss dosages or adherence.
C. Yes. Alternatives and drug class described.
D. Yes. Treatments discussed in Background and branded/generic noted.

Answer: D. Yes. The authors clearly described the two different treatments in the Background and discussed whether they were generic or branded.

Question: Was the perspective of the Crestor vs Cholestyramine study clearly stated?

Answer Options:
A. Yes. Study done from hospital perspective.
B. Yes. They used medical claims.
C. No. Used hospital charges but perspective not clearly stated.
D. None of the above

Answer: C. No. Although the authors state that they used hospital charges, they do not clearly state the perspective of the study.

Question: Were the assumptions stated and reasonable in the cost-minimization study comparing Crestor and Cholestyramine?

Answer Options:
A. Yes. The authors clearly stated all of their assumptions.
B. Yes. The authors stated that there were no assumptions.
C. No. The authors did not explicitly state many of their assumptions.
D. None of the above

Answer: C. No. The authors did not explicitly state many of their assumptions.

Question: Present value of treatment with Megastatin (3 years: $10k, $10k, $100k; 3% discount)?

Answer Options:
A. $126,390
B. $120,000
C. $113,968
D. $110,000
E. Cannot tell without Medical Consumer Price Index

Answer: C. $113,968

Question: Was the conclusion unbiased and supported by the study methods?

Answer Options:
A. No. The choice of an old generic drug is suspect.
B. No. The conclusion that one drug provides “the best value” is unfounded considering only two drugs were compared.
C. No. Charges and AWP were not accurate reflections of cost.
D. No. Cost-minimization ignores differences in effectiveness.
E. All of the above

Answer: E. All of the above

Question: What is the ICER of DrugA vs DrugB? (DrugA: $20k/10yrs, DrugB: $8k/4yrs)

Answer Options:
A. $1000 per life year
B. $2000 per life year
C. $600 per life year
D. $8000 per life year
E. $1600 per life year

Answer: A. $1000 per life year

Question: Best type of pharmacoeconomic study for comparing Firstatin and Secondstatin (similar efficacy and side effects)?

Answer Options:
A. Cost-minimization
B. Cost-utility
C. Cost-of-illness
D. Cost-effectiveness
E. None of the above

Answer: A. Cost-minimization

Question: Was a clear objective stated in the Crestor vs Cholestyramine study?

Answer Options:
A. No. Does not state perspective.
B. No. Does not declare specific type of study.
C. Yes. Specifies type of study and treatments.
D. Yes. Objective is well-defined and aligned.

Answer: D. Yes. The objective poses a well-defined question and is aligned with the study conducted.

Question: Is cost-minimization appropriate when comparing DrugX and DrugY (equal survival, different adverse effects)?

Answer Options:
A. No. Cost-utility would be better
B. Yes. Outcomes are different but cost-min is still best
C. Yes. Outcomes are same, and cost-min is best
D. No. Cost-effectiveness is better due to survival differences
E. None of the above

Answer: A. No. The increase in survival is the same but there are differences in adverse effects so cost-minimization is not appropriate.

Question: Which drug is cost-effective? (DrugX $8,000 for 5 yrs vs DrugY $3,000 for 15 yrs)

Answer Options:
A. DrugX dominates DrugY
B. ICER is $1,000/life year; depends on if extra cost is worth benefit
C. DrugX is dominated by DrugY
D. We cannot determine from the information given

Answer: C. DrugX is dominated by DrugY